Immutep (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average of $2.72

Immutep Limited (NASDAQ:IMMPGet Free Report)’s share price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.72 and traded as high as $2.86. Immutep shares last traded at $2.85, with a volume of 385,147 shares traded.

Wall Street Analyst Weigh In

Separately, Capital One Financial initiated coverage on Immutep in a research report on Friday, May 17th. They set an “overweight” rating and a $10.00 target price on the stock.

Check Out Our Latest Analysis on Immutep

Immutep Price Performance

The stock has a 50 day simple moving average of $2.73 and a 200 day simple moving average of $2.45.

Institutional Investors Weigh In On Immutep

Several hedge funds have recently made changes to their positions in the company. PFG Investments LLC bought a new stake in Immutep in the first quarter worth $119,000. Oracle Investment Management Inc. grew its holdings in Immutep by 9.4% during the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after purchasing an additional 48,449 shares during the period. Virtu Financial LLC grew its holdings in Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 32,864 shares during the period. Meridian Wealth Management LLC grew its holdings in Immutep by 3.6% during the fourth quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 11,250 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 4,700 shares during the period. 2.32% of the stock is currently owned by institutional investors.

About Immutep

(Get Free Report)

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

See Also

Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.